oth single-use phased
array and rotational IVUS imaging catheters, and advanced functionality
options, such as VH(TM) IVUS tissue characterization and ChromaFlo(R).
Volcano also provides functional measurement (FM) consoles and single-use
pressure and flow guide wires. Currently, more than 2,900 Volcano IVUS and
FM systems are installed worldwide, with approximately half of its revenues
coming from outside the United States. For more information, visit the
company's website at
http://www.volcanocorp.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any
statements in this news release regarding the CardioSpectra acquisition,
Volcano's business and technology, and CardioSpectra's business and
technology, that are not historical facts may be considered
"forward-looking statements," including statements regarding the
CardioSpectra acquisition, its expected benefits to Volcano and
CardioSpectra, the complementary nature of each company's technology and
skill sets to the other, Volcano's long-term goals from the CardioSpectra
acquisition, and the features of CardioSpectra's technology and its
potential. Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and uncertainties, which
may cause Volcano's results to differ materially and adversely from the
statements contained here. Some of the potential risks and uncertainties
that could cause actual results to differ from the results predicted are
detailed in the company's annual report on Form 10-K, quarterly reports on
Form 10-Q and other filings made with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Volcano
undertakes no obligation to update any forward-looking statements to
r
'/>"/>
SOURCE Volcano Corporation Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Volcano Corporation Presentation at Bear Stearns Conference to be Webcast2.
Volcano Corporation Announces Pricing of Common Stock Offering3.
Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated4.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients5.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 266.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering7.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.8.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets9.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results10.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain11.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter